Multiple Sclerosis

Articles on this topic

Epstein-Barr Virus –⁠ Is the Culprit of MS Revealed?

Could the Epstein-Barr virus hold the answer to the etiology of multiple sclerosis? A dataset…

23. 5. 2022 Source: Multiple Sclerosis

Gut-Brain Axis −⁠ Future of MS Treatment?

The relationship between the gut microbiome and multiple sclerosis has been a major topic…

3. 5. 2022 Source: Multiple Sclerosis

Teriflunomide under the microscope in studies and practice

Not always do the conclusions from clinical studies fully confirm in real clinical practice.…

3. 5. 2022 Source: Multiple Sclerosis

How Do Vaccinated MS Patients Fare with COVID-19 Antibodies?

Which disease-modifying drugs for the treatment of multiple sclerosis (MS) reduce the humoral…

21. 12. 2021 Source: Multiple Sclerosis

When Teriflunomide and Interferon Join Forces

Progressive multifocal leukoencephalopathy is a nightmare for all doctors prescribing…

21. 12. 2021 Source: Multiple Sclerosis

Alemtuzumab –⁠ Does Age Matter? Or Not?

The authors of a study published this year focused on the safety and efficacy of alemtuzumab…

18. 10. 2021 Source: Multiple Sclerosis

Does Teriflunomide Bloom at Every Age?

What impact does age have on the effectiveness of multiple sclerosis (MS) therapy in…

18. 10. 2021 Source: Multiple Sclerosis

medicína_lékař_mikroskop_studie_výzkum_laboratoř

Teriflunomide vs. Dimethyl Fumarate in Real Practice: We Know the Winner! Will It Surprise You?

Teriflunomide and dimethyl fumarate are disease-modifying drugs (DMDs) used in the treatment of...

31. 7. 2021 Source: Multiple Sclerosis

MS, NMOSD and COVID-19: What Did a Year of Pandemic in Czechia Mean for Our Patients and Which Risk Factors Were Confirmed?

What is the incidence and course of COVID-19 in patients with multiple sclerosis (MS) and diseases...

28. 7. 2021 Source: Multiple Sclerosis

PL_preklad_studium_studie_vyzkum_data_zprava

How did alemtuzumab fare in real clinical practice?

A study published by authors from the University of Massachusetts in January this year in the…

11. 6. 2021 Source: Multiple Sclerosis

COVID-19 and MS: Do You Know the Risk Factors? What the American Registry Analysis Showed

An article published in the March issue of the prestigious journal JAMA Neurology summarizes…

19. 4. 2021 Source: Multiple Sclerosis

Fatigue in Multiple Sclerosis: What Can Teriflunomide Do?

An article by French authors published in January this year in the journal Multiple Sclerosis…

19. 4. 2021 Source: Multiple Sclerosis

těhotenství_žena _medicína_genetika_rodiče_rodina

Teriflunomide and Pregnancy Planning

The authors of the article published last year in Multiple Sclerosis Journal present data…

25. 3. 2021 Source: Multiple Sclerosis

Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?

The results of the TOWER study extension were published this August in the prestigious journal…

17. 12. 2020 Source: Multiple Sclerosis

Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles

The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the…

18. 11. 2020 Source: Multiple Sclerosis

1 2 3

E-courses on this topic

Authors: MUDr. Radek Ampapa

Course detail

Authors: MUDr. Eva Němá, Ph.D.

Course detail

Authors: MUDr. Jiří Slíva, Ph.D.

Course detail

Conferences news

8. OLOMOUCKÉ NEUROIMUNOLOGICKÉ SYMPOZIUM

20. 9. 2012 - 21. 9. 2012

18 records

Go to records

25. Český a Slovenský Neurologický sjezd

23. 11. 2011 - 26. 11. 2011

10 records

Go to records

15. Jedličkovy neuroimunologické a likvorologické dny

13. 5. 2011 - 14. 5. 2011

9 records

Go to records

24. Český a Slovenský Neurologický sjezd

24. 11. 2010 - 27. 11. 2010

6 records

Go to records